# YF476 and Type I Gastric Carcinoids (Norway)

> **NCT01444014** · PHASE2 · TERMINATED · sponsor: **Trio Medicines Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Chronic Atrophic Gastritis
- Hypergastrinemia
- Type I Gastric Carcinoids

## Interventions

- **DRUG:** YF476

## Key facts

- **NCT ID:** NCT01444014
- **Lead sponsor:** Trio Medicines Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Difficulties with recruitment
- **Last updated:** 2015-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01444014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01444014, "YF476 and Type I Gastric Carcinoids (Norway)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01444014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*